Recently, according to report, Kenvue has announced another round of layoffs affecting its newly established headquarters in Summit, New Jersey. The company disclosed plans to cut 69 positions between October 10th and December 19th.
In a filing with the New Jersey Department of Labor & Workforce Development, Kenvue emphasized its ongoing evolution to enhance operational efficiency and innovation capabilities aimed at broader consumer reach. A spokesperson for Kenvue conveyed the difficulty of such decisions, emphasizing their commitment to supporting affected employees through this transition.
Despite the layoffs, Kenvue anticipates a net increase in job opportunities in New Jersey following the completion of its transition to the new Summit headquarters. The relocation from a temporary base in Skillman to a spacious 292,000-square-foot facility represents a pivotal step in consolidating operations. Last year, Kenvue had already downsized with 51 local job cuts, alongside the relocation of its Neutrogena brand from California, impacting an additional 84 employees.
This restructuring initiative forms part of Kenvue’s strategic plan to achieve approximately $350 million in annual pre-tax savings by 2026. With a robust portfolio encompassing renowned brands like Band-Aid, Listerine, Tylenol, and Benadryl, Kenvue remains a significant player in the consumer health sector, boasting $15.44 billion in revenue for 2024.
